Although researchers have not directly shown that high FOXM1 expression results in drug resistance, they suggest that the FOXM1-AKT cycle upregulates the MCL-1 protein through sustained activation of the AKT pathway, promoting the development of drug resistance to venetoclax in AML (29). The gene discussed is AKT1; the disease is acute myeloid leukemia.